News
-
-
-
COMMUNIQUÉ DE PRESSE
Skyhawk Therapeutics Appoints Aaron Deves as Chief Commercial Officer to Lead Commercialization of SKY-0515 for Huntington's Disease
Skyhawk Therapeutics appoints Aaron Deves as Chief Commercial Officer to drive SKY-0515 launch for Huntington's Disease. Deves brings extensive experience in launching therapies for neurological diseases -
-
-
COMMUNIQUÉ DE PRESSE
Skyhawk Announces Australia's Therapeutic Goods Administration Has Determined SKY-0515 for Huntington's Disease Meets Eligibility Criteria for Registration via the Provisional Approval Pathway
Skyhawk Therapeutics announces that Australia's Therapeutic Goods Administration has determined SKY-0515 for Huntington's Disease meets eligibility criteria for provisional registration pathway -
-
-
COMMUNIQUÉ DE PRESSE
Skyhawk Therapeutics Announces Nine Month Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington's Disease
Skyhawk Therapeutics reports positive interim results in Phase 1 Clinical Trial of SKY-0515 for Huntington's Disease, showing promising data on disease progression and safety
